Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9360741 | 1.00 | CISD1 (0.56) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9365521 | 0.94 | CISD1 (0.56) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9365514 | 0.94 | CISD1 (0.56) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9361052 | 0.92 | CISD1 (0.54) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9361056 | 0.92 | CISD1 (0.54) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL23572562 | 0.91 | PTGES (0.55) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL9360606 | 0.91 | PTGES (0.55) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL21625779 | 0.91 | CISD1 (0.52) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL21625780 | 0.91 | CISD1 (0.52) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL29918400 | 0.91 | PTGES (0.55) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110217783-A1 | CLEAVABLE SURFACTANTS AND METHODS OF USE THEREOF | VANDERBILT UNIVERSITY | 2011-09-08 | — | — | US | disclosed |
| EP-0335641-B1 | Organic nonlinear optical substance | TEIJIN LTD (JP) | 1994-01-05 | — | — | EP | disclosed |
| US-5196147-A | Optical crystals | TEIJIN LIMITED (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0335641-A2 | Organic nonlinear optical substance | TEIJIN LIMITED (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217783-A1 | CLEAVABLE SURFACTANTS AND METHODS OF USE THEREOF | PHOSPHO1, SGMS1, SGMS2 | CISD1 2400/4885KDM4E 4601/4885SLC16A3 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.